Can a new drug combo outsmart resistant myeloma?

NCT ID NCT07742215

Recruiting now Disease control Sponsor: Biocad Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This phase III trial is investigating whether adding an experimental drug called BCD-248 to daratumumab can improve outcomes for people with multiple myeloma that has returned or become resistant to treatment. The study will compare this new combination against the current standard of daratumumab, pomalidomide, and dexamethasone. Participants are adults with confirmed multiple myeloma who have had one to three prior lines of therapy. The main goals are to see if the new combo increases the chance of achieving a deep remission and extends the time before the disease progresses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BCD-248 combined with daratumumab
What this could lead to: If successful, this combination could offer a new, more effective treatment option for people with multiple myeloma that has returned or stopped responding to prior therapies.
What could go wrong: This is an early-stage comparison, and the new combination may not prove better than the existing regimen. Side effects are possible, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOMA MULTIPLE

Contacts and locations

Locations

BHI of the Omsk region "Clinical Oncological Dispensary"
RECRUITING

Omsk, Russia
Branch Office of Hadassah Medical Ltd.
RECRUITING

Moscow, Russia
FSBEI HE "Saratov State Medical University named after V.I. Razumovsky" of the Ministry of Health of Russia
RECRUITING

Saratov, Russia
FSBEI of Higher Education "Samara State Medical University" of the Ministry of Health of the Russian Federation
RECRUITING

Samara, Russia
FSBI "National Medical Research Center named after V.A. Almazov" of the Ministry of Health of the Russian Federation
RECRUITING

Saint Petersburg, Russia
FSBI "Russian Research Institute of Hematology and Transfusiology" of the Federal Medical and Biological Agency
RECRUITING

Saint Petersburg, Russia
Private healthcare institution "Clinical hospital "RZD-Medicine" of the city of Smolensk"
RECRUITING

Smolensk, Russia
Regional Government-Owned Publicly Funded Healthcare Institution "Regional Clinical Hospital"
RECRUITING

Krasnoyarsk, Russia
SAHI "Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor M.Z. Sigal"
RECRUITING

Kazan', Russia
SBHI "Chelyabinsk regional clinical hospital"
RECRUITING

Chelyabinsk, Russia
SBHI "Leningrad Regional Clinical Hospital"
RECRUITING

Saint Petersburg, Russia
SBHI "Regional oncological dispensary"
RECRUITING

Irkutsk, Russia
SBHI "Republican Clinical Hospital named G.G. Kuvatov"
RECRUITING

Ufa, Russia
SI "Republican Scientific and Practical Center for Radiation Medicine and Human Ecology"
RECRUITING

Homyel, Belarus
St. Petersburg State Healthcare Institution "City Hospital No. 15"
RECRUITING

Saint Petersburg, 190000, Russia
State Budgetary Healthcare Institution "Oncological Dispensary No.2" of the Ministry of Health of the Krasnodar Region
RECRUITING

Sochi, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.